Madrigal Pharmaceuticals (STU:YDO1) COGS-to-Revenue : 0.00 (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Madrigal Pharmaceuticals COGS-to-Revenue?

Madrigal Pharmaceuticals's Cost of Goods Sold for the three months ended in Dec. 2023 was €0.00 Mil. Its Revenue for the three months ended in Dec. 2023 was €0.00 Mil.

Madrigal Pharmaceuticals's COGS to Revenue for the three months ended in Dec. 2023 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Madrigal Pharmaceuticals's Gross Margin % for the three months ended in Dec. 2023 was N/A%.

Madrigal Pharmaceuticals COGS-to-Revenue Historical Data

The historical data trend for Madrigal Pharmaceuticals's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Madrigal Pharmaceuticals COGS-to-Revenue Chart

Madrigal Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

COGS-to-Revenue

Get a 7-Day Free Trial

Madrigal Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
COGS-to-Revenue	Get a 7-Day Free Trial															-	-	-	-	-

Madrigal Pharmaceuticals COGS-to-Revenue Calculation

Madrigal Pharmaceuticals's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	0
	=

Madrigal Pharmaceuticals's COGS to Revenue for the quarter that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	0
	=

Madrigal Pharmaceuticals (STU:YDO1) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Madrigal Pharmaceuticals's Gross Margin % for the three months ended in Dec. 2023 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	0 / 0
	=	N/A %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Madrigal Pharmaceuticals COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Madrigal Pharmaceuticals's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Madrigal Pharmaceuticals (STU:YDO1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Madrigal Pharmaceuticals Inc (STU:YDO1) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

MDGL:USA YDO1:Germany

Address

200 Barr Harbor Drive, Suite 200, Four Tower Bridge, West Conshohocken, PA, USA, 19428

Website

http://www.madrigalpharma.com

Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.

Madrigal Pharmaceuticals (STU:YDO1) Headlines

No Headlines